Application of retinoid substance as CLCA1 protein expression promoter or inducer in promoting bifidobacterium colonization in intestinal tract
By regulating the expression of intestinal CLCA1, retinoid substances are used to promote the interaction between Bifidobacterium and atpH protein, the problem of difficulty in colonizing Bifidobacterium is solved and the effect and stability of probiotic treatment is improved.
Patent Information
- Application Number
- CN202410953472.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-16
- Publication Date
- 2024-11-22
AI Technical Summary
There is a lack of effective methods in the prior art to improve the colonization of Bifidobacterium in the intestine, resulting in unstable therapeutic efficacy and low response sensitivity of probiotics, and the relationship between retinoid substances and Bifidobacterium intestine colonization has not been studied.
By using retinoid substances such as retinoic acid and vitamin A, the expression of the host intestinal mucin CLCA1 is regulated, and it promotes its interaction with the atpH protein on the surface of Bifidobacterium, thereby improving Bifidobacterium colonization ability.
It has achieved efficient colonization of Bifidobacterium in the intestine, enhanced the efficacy and long-term maintenance of probiotic treatment, and provided a safe and feasible clinical application approach.
Smart Images

Figure CN118986953A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of microbial application, and in particular to the application of retinoic acid-like substances (Retinoids) as CLCA1 protein (Monoclonal Antibody to Chloride Channel Accessory 1, chloride channel auxiliary protein 1) expression promoters or inducers in promoting bifidobacterium colonization in the intestine. Background Art
[0002] Bifidobacterium is the main flora in the human colon, accounting for 25% of the culturable fecal bacteria in adults. Especially during the neonatal period, bifidobacterium is the earliest colonized and the most important dominant bacteria in the intestine. Bifidobacterium not only has nutritional functions, such as metabolizing vitamins and fatty acids to promote growth, but also can play an anti-infection, protect the intestinal barrier and anti-cancer role. Therefore, the colonization of bifidobacteria in infancy plays an important role in the healthy growth of infants and young children. Intestinal bifidobacteria not only play an important role in human growth, but it is also one of the most widely used probiotics in clinical treatment. For example, the common bifidobacterium triple live capsule is often used to treat acute and chronic diarrhea and constipation caused by intestinal flora imbalance. It can also be used for mild and moderate acute diarrhea, chronic diarrhea, indigestion, abdominal distension, and can even be used as an auxiliary treatment for endotoxemia caused by flora imbalance. In recent years, with the development of technology, the application and physiological effects of bifidobacteria have also been greatly expanded. For example, the application research of bifidobacteria has been extended to the treatment of neurological diseases, such as alleviating autism spectrum disorders, anxiety, Parkinson's disease and Alzheimer's disease through the "gut-brain" axis; delaying osteoporosis and reducing the risk of fractures through the "gut-bone" axis. The research and expansion of these therapeutic applications have accelerated the clinical application transformation of bifidobacteria and further demonstrated the importance of bifidobacteria in clinical applications.
[0003] Probiotic treatments, including Bifidobacterium, generally encounter the bottleneck of difficult probiotic colonization. If we consider the bacterial colonization mechanism from an ecological perspective, then both "seeds" (bacteria) and "soil" (intestinal ecosystem) are extremely important. Successful bacterial colonization requires that the strains have the ability to resist the harsh intestinal environment and have an appropriate surface structure to attach to the intestinal epithelium and mucus. There are many factors that affect the colonization of intestinal flora, such as some genes and proteins of the bacteria themselves that can inhibit the stress of gastric acid and bile acid, produce tolerance to the immune system, and improve the metabolic capacity of the bacteria themselves. At the same time, bacterial structures such as flagella will also affect bacterial colonization by interacting with the host epithelium; the host's daily diet, age, gender, and genetic defects will also affect bacterial colonization.
[0004] Based on the above factors that affect bacterial colonization, the following approaches can be considered: (1) Genetically modifying microorganisms through screening or bioengineering technology to obtain a better colonization strain; (2) Structural analysis of bacterial surface molecules to further understand and predict the molecular mechanism of host-microorganism interaction; (3) Adding certain prebiotics to the diet so that probiotics can obtain better nutrition and improve vitality; (4) Optimizing the "soil", that is, improving the intestinal environment of the host, thereby facilitating the colonization of bifidobacteria.
[0005] However, no feasible methods have been developed to improve the colonization of probiotics (especially bifidobacteria) for the following reasons: (1) There are few studies on the colonization mechanism of probiotics, especially bifidobacteria, which leads to fewer related transformation applications; (2) Bacteria of the same genus often have great differences in morphology and gene expression, which means that the colonization mechanism or colonization method found in a certain microorganism is not valid for different bacteria of the same genus; (3) There are not many suitable gene editing tools for the genetic modification of some prebiotics. Although CRISPR-Cas9 gene editing technology is quite mature, its application in microorganisms needs to be further optimized in terms of methodology; at the same time, genetically modified microorganisms still need more vigilance in terms of biosafety. All these limit the clinical application of genetically modified microorganisms.
[0006] In the currently used probiotic or intestinal flora transplantation treatment programs, once the use of probiotics is stopped, the abundance of probiotics in the intestines will decrease rapidly, and the probiotics will be quickly lost with fecal excretion; at the same time, whether the probiotics are efficiently colonized often predicts the efficacy and response sensitivity of the probiotics. Therefore, the research on probiotic colonization, especially the colonization mechanism of bifidobacteria and the development of technologies and means to promote the rapid and efficient colonization of probiotics such as bifidobacteria, is of great significance for improving the efficacy of probiotic treatment in the future.
[0007] Retinoids include retinoic acid and precursor compounds such as retinal, retinol and vitamin A. They all have similar nucleus structures and are a large class of substances derived from vitamin A. The human body cannot synthesize vitamin A normally, and needs to obtain vitamin A from food. Then, vitamin A in the body is metabolized by a series of enzymes to produce retinol, retinal and retinoic acid in turn. Retinoic acid is the final executor of the retinoic acid signaling pathway in the body and has the greatest activation effect. Retinoids are mainly used clinically for the treatment of skin diseases and inflammatory skin diseases, skin cancer and skin wrinkles; vitamin A is mainly used clinically for the treatment of night blindness, dry eye disease, corneal softening, etc., and it also plays an important regulatory role in the normal development of fetuses and infants. Retinoic acid (RA) is commonly known as tretinoin and retinoic acid in clinical practice. It is mainly used clinically for the treatment of acne and acute promyelocytic leukemia. Retinoic acid is used in the form of creams, gels and ointments for the treatment of acne; for the treatment of acute promyelocytic leukemia, retinoic acid is often taken orally. Bifidobacterium is commonly used clinically for digestive diseases such as acute and chronic diarrhea, abdominal pain, constipation and indigestion. In microbiota transplantation therapy, bifidobacteria are also the main functional bacteria; currently, bifidobacteria have also played a good therapeutic effect in non-digestive diseases such as autism spectrum disorder and non-alcoholic fatty liver disease. However, there is still a lack of research on the colonization mechanism of bifidobacteria, and there are no reports on the relationship between retinoic acid-like substances and intestinal bifidobacterium colonization. Summary of the invention
[0008] In order to overcome at least one problem existing in the prior art, the present invention deeply studies the potential molecular mechanism of the interaction between bifidobacteria and the host, and by utilizing the molecular mechanism of the interaction between bifidobacteria and the host, seeks means to optimize the intestinal environment of the host, thereby achieving efficient colonization of bifidobacteria by optimizing the intestinal environment of the host.
[0009] To achieve the above object, the present invention adopts the following technical solution:
[0010] The first aspect of the present invention is to provide the use of a CLCA1 protein expression promoter or inducer in promoting the colonization of bifidobacteria in the intestine.
[0011] Furthermore, the CLCA1 protein expression promoter or inducer increases the expression of CLCA1 protein in intestinal epithelial tissue, and the CLCA1 protein interacts with atpH protein on the surface of bifidobacteria, thereby promoting the colonization of bifidobacteria in the intestine.
[0012] Furthermore, the CLCA1 protein expression promoter or inducer includes a retinoic acid-like substance.
[0013] Furthermore, the retinoic acid-like substances include retinoic acid and vitamin A. It is understandable that the CLCA1 protein expression promoter also includes other small molecules or macromolecules that can achieve overexpression of CLCA1 protein, such as retinol and retinal.
[0014] Furthermore, the bifidobacterium includes any one or several bifidobacteria in the genus Bifidobacterium, such as bifidobacteria commonly found in the human intestine, bifidobacteria from animals, etc.; specifically, the bifidobacterium includes at least one of Bifidobacterium bifidum, Bifidobacterium adolescentis, Bifidobacterium infantis, Bifidobacterium pseudolongum, Bifidobacterium longum, Bifidobacterium breve, etc.; preferably at least one of Bifidobacterium pseudolongum and Bifidobacterium longum.
[0015] Furthermore, the expression level of the CLCA1 protein can be used as an evaluation index for clinical FMT and probiotic (including bifidobacterium) treatment.
[0016] The second aspect of the present invention is to provide the use of retinoic acid-like substances as promoters or inducers of CLCA1 protein expression.
[0017] Furthermore, the retinoic acid-like substances include retinoic acid and vitamin A.
[0018] Furthermore, there is a retinoic acid binding site in the promoter region of the CLCA1 protein, and the retinoic acid-like substance promotes the expression of the CLCA1 protein in the intestinal epithelial tissue through the retinoic acid signaling pathway.
[0019] Furthermore, the retinoic acid binding site is the 509-527 bp site upstream of the CLCA1 protein promoter. Specifically, the specific sequence of the retinoic acid binding site is: AGGTTATGTCAAGGTAA.
[0020] Furthermore, the retinoic acid-like substance is used as a promoter or inducer of CLCA1 protein expression to promote the colonization of bifidobacteria in the intestine.
[0021] Furthermore, the retinoic acid-like substance promotes the expression of CLCA1 protein in intestinal epithelial tissue through the retinoic acid signaling pathway, and the CLCA1 protein interacts with atpH protein on the surface of bifidobacteria, thereby promoting the colonization of bifidobacteria in the intestine.
[0022] Furthermore, the expression level of the CLCA1 protein can be used as an evaluation index for clinical FMT and probiotic (including bifidobacterium) treatment.
[0023] Furthermore, the bifidobacterium includes any one or several bifidobacteria in the genus Bifidobacterium, such as bifidobacteria commonly found in the human intestine, bifidobacteria from animals, etc.; specifically, the bifidobacterium includes at least one of Bifidobacterium bifidum, Bifidobacterium adolescentis, Bifidobacterium infantis, Bifidobacterium pseudolongum, Bifidobacterium longum, Bifidobacterium breve, etc.; preferably at least one of Bifidobacterium pseudolongum and Bifidobacterium longum.
[0024] Furthermore, the retinoic acid-like substance is used as an adjuvant for intestinal flora transplantation or as an adjuvant for probiotic treatment.
[0025] Furthermore, in in vitro experiments, the retinoic acid-like substance (specifically retinoic acid) is used at a final concentration of 2nM-10μM (preferably a final concentration of 1μM), and is used by directly adding the retinoic acid-like substance to the culture medium; in animal experiments, the retinoic acid-like substance (specifically retinoic acid) is dissolved in olive oil and administered to mice by gavage at a concentration of 10-20mg / kg / day (preferably 15mg / kg / day) for two consecutive weeks.
[0026] When using probiotics containing bifidobacteria for health care and prevention of related diseases, oral administration of a certain amount of retinoic acid or vitamin A at the same time can amplify the health care and therapeutic effects.
[0027] Intestinal flora transplantation (FMT) treatment has shown certain efficacy in clinical studies of inflammatory bowel disease, irritable bowel syndrome, functional constipation, cirrhosis, autism and other diseases. Bifidobacterium is one of the important bacterial genera of FMT. The effective colonization of Bifidobacterium can better exert the efficacy of FMT and maintain the long-term therapeutic effect of FMT. Therefore, when using FMT to treat related diseases, oral administration of a certain amount of retinoic acid or vitamin A can amplify the therapeutic effect.
[0028] Compared with the prior art, the present invention adopts the above technical solution to have the following beneficial effects:
[0029] In order to better enable bifidobacteria to colonize in the intestine and exert the functions of bifidobacteria, the present invention has found through research that retinoic acid-like substances (including retinoic acid and vitamin A) can increase the expression of intestinal mucin CLCA1, and CLCA1 can interact with atpH protein on the surface of bifidobacteria, thereby facilitating the colonization of bifidobacteria.
[0030] The present invention is the first to find that the expression of a gene in the host intestine can be used to enhance the colonization of bifidobacteria, and it is also the first to find that the CLCA1 protein can interact with bifidobacteria, thereby regulating the colonization of bifidobacteria. Based on the fact that retinoic acid-like substances have been used in clinical practice, it is feasible and safe to promote the colonization of bifidobacteria by regulating the expression of intestinal CLCA1 using retinoic acid or vitamin A. Retinoic acid or vitamin A can regulate the expression of CLCA1 on the intestinal epithelium by activating the retinoic acid signaling pathway, and CLCA1 can specifically interact with bifidobacteria, thereby facilitating the colonization of bifidobacteria. Therefore, in clinical probiotics or intestinal flora transplantation treatment programs, if the abundance of CLCA1 is low, patients can be allowed to take retinoic acid-like substances, such as retinoic acid or vitamin A, to increase the expression of intestinal CLCA1, thereby maximizing the therapeutic effect of probiotics. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] The drawings described herein are used to provide a further understanding of the present invention and constitute a part of the present invention. The exemplary embodiments of the present invention and their descriptions are only used to explain the present invention and do not constitute an improper limitation of the present invention. In the drawings:
[0032] Figure 1 This is a schematic diagram of the results of searching for proteins that interact with bifidobacteria in the intestinal tissue of a host in one embodiment of the present invention;
[0033] Figure 2 This is a schematic diagram of the results of verifying that the atpH protein of Bifidobacterium pseudolongum can interact with the host's CLCA1 protein in one embodiment of the present invention;
[0034] Figure 3 This is a schematic diagram of the results of verifying whether the interaction between bacterial atpH protein and host CLCA1 is specific in one embodiment of the present invention;
[0035] Figure 4 This is a schematic diagram of the results of verifying that the interaction between host CLCA1 and bifidobacteria can promote the colonization of bifidobacteria in one embodiment of the present invention;
[0036] Figure 5 This is a schematic diagram of the results of verifying that retinoic acid and vitamin A can increase the expression of CLCA1 to promote the colonization of bifidobacteria in one embodiment of the present invention. DETAILED DESCRIPTION
[0037] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in the field without creative work belong to the scope of protection of the present invention. The experimental methods without specific conditions in the following embodiments are usually measured according to national standards. The experimental materials without the source indicated in the following embodiments are all commercially available raw materials. The equipment used in each step in the following embodiments is conventional equipment. If there is no corresponding national standard, it is carried out according to the general international standards, conventional conditions, or according to the conditions recommended by the manufacturer. Unless otherwise specified, all parts are weight parts and all percentages are mass percentages. Unless otherwise defined or specified, all professional and scientific terms used in the present invention have the same meaning as those familiar to those skilled in the art. In addition, any method and material similar or equal to the recorded content can be applied to the method of the present invention.
[0038] It should be noted that, in the absence of conflict, the embodiments of the present invention and the features in the embodiments can be combined with each other. The present invention is further described below in conjunction with the drawings and specific embodiments, but is not intended to be a limitation of the present invention.
[0039] In the following embodiments, HIEC6 cells: laboratory preserved cells, purchased from ATCC, catalog number: CRL-3266; mice: C57 wild mice purchased from Shanghai Slake Laboratory Animal Co., Ltd.; organoids from mouse tissue: intestinal organoids are from C57 wild mice, isolated and cultured in the laboratory; Escherichia coli: DH5α Escherichia coli purchased from Shanghai Weidi Biotechnology Co., Ltd., catalog number: DL1001; Pseudomonas longum was purchased from Ningbo Mingzhou Biotechnology, catalog number: B89636; Bifidobacterium longum, Enterococcus faecalis and Lactobacillus animalis are all laboratory-isolated and preserved bacteria.
[0040] In the following examples, sequence analysis shows that, in principle, the atpH protein on the surface of any bifidobacterium of the genus Bifidobacterium can interact with the CLCA1 protein, thereby promoting the colonization of bifidobacteria in the intestine. In actual research, only Bifidobacterium pseudolongum and Bifidobacterium longum were used as examples for verification.
[0041] Example 1 - Searching for Bifidobacterium and Intestinal Epithelial Tissue Interacting Proteins by Molecular Biology
[0042] In order to find a method to promote the colonization of bifidobacteria, this example starts from the interaction between bacteria and host proteins to find proteins that interact with bifidobacteria and host intestinal epithelial tissue. This example uses molecular biological methods such as Far-western analysis to find interacting proteins. The specific method includes:
[0043] First, the cell membrane proteins of bifidobacteria were biotinylated using an amine-reactive biotinylation reagent Sulfo-NHS-LC-Biotin sodium (MCE, catalog number: HY-D0799). The relevant experimental steps are as follows: the cultured bifidobacteria were centrifuged and washed once with pre-cooled PBS, and then incubated with Sulfo-NHS-LC-Biotin sodium at a final concentration of 1 mM at 4°C for 2 hours, and then 100 mM glycine was added to terminate the reaction. The bacteria were then centrifuged and washed three times with cold PBS. The bacterial pellet was obtained by centrifugation and weighed. A certain amount of lysis buffer (50 mM Tris-HCl, PH = 8, 1 mM EDTA, 50 mM NaCl, 1 mM PMSF) and 300 μg / mL of lysozyme were added to resuspend the bacteria and placed on ice for lysis for 30 minutes. 1% Triton x-100 was then added and the cells were broken using an ultrasonic disruptor. 10 mg / kg of Dnase I and 10 mM MgCl2 were added to the broken product and placed on ice for 10 minutes. Finally, the supernatant was collected at 4 ° C and 10000g for 15 minutes, which was the biotinylated bifidobacterium cell membrane protein. At the same time, the intestinal epithelial tissue and mucus layer in the small intestine of wild-type mice C57 (Slack Laboratory Animal Co., Ltd.) were collected; the epithelial tissue and mucus layer proteins were lysed using RIPA lysis buffer (Biyuntian, Catalog No.: P0013B), and then the proteins of the epithelial tissue and intestinal mucus layer were transferred to the NC membrane by Western Blot, and then the biotinylated bacterial membrane protein was used as the primary antibody to incubate with the protein on the NC membrane overnight, and then HRP-streptavidin (Biyuntian, Catalog No.: A0303) was used for incubation, and after incubation, it was washed three times with TBST solution and developed with WB color development solution (Merck, Catalog No.: WBKLS). If there are proteins on the bifidobacterial cell membrane that interact with the proteins of the mouse intestinal epithelium or mucus layer, then there will be corresponding bands when the color image is developed. After that, the intestinal epithelial tissue and mucus layer proteins are again stained with SDS-PAGE gel and Coomassie Brilliant Blue to find the corresponding band position. The band is cut off and sent for protein spectrum identification to find potential proteins that interact with the bifidobacterium cell membrane and the host.
[0044] like Figure 1 As shown in Part A, the cell membranes of Bifidobacterium longum (laboratory seed strain) and Bifidobacterium pseudolongum (Mingzhou Biotechnology, Catalog No.: B89636) were successfully biotinylated using an amine-reactive biotinylation reagent. The biotinylated proteins can be clearly seen after incubation with HRP-Streptavidin for color development; Figure 1As shown in Part B, using the Far-western blot method, the biotinylated bacterial membrane protein group has multiple colored bands compared with the non-biotinylated membrane protein group. These bands may be potential host and bifidobacterium interaction proteins. Then, Coomassie Brilliant Blue (Biyuntian, Catalog No.: P0003S) was used for staining to find the position of the corresponding band, and the protein spectrum was cut out for identification; Figure 1 As shown in part C, through protein spectrum identification, the intersection of the epithelial tissue group and the intestinal mucus layer group was taken, and it was found that these potential intersection proteins contained the mucin CLCA1, which is very likely a protein for the interaction between bifidobacteria and the host.
[0045] From the above experimental results, it can be seen that by using the above method, multiple potential interacting proteins were identified in the epithelial tissue and mucus layer respectively; by taking the intersection of the two, it was found that the CLCA1 mucin in the mouse intestine is likely to interact with the bifidobacterium cell membrane, because this protein is a classic mucin secreted by goblet cells, which plays an important regulatory role in bacterial colonization and reproduction.
[0046] Example 2 - Further search for the exact protein on the cell membrane of Bifidobacterium that interacts with CLCA1 protein
[0047] In this example, in order to further find the exact protein on the cell membrane of bifidobacteria and confirm that the protein can interact with the CLCA1 protein in the host intestine, that is, in order to find the protein on the cell membrane of bifidobacteria that can interact with the host CLCA1, the His-pulldown method is used to find the membrane protein that interacts with CLCA1. The specific method includes:
[0048] (1) First, a His-tagged CLCA1 eukaryotic expression plasmid was constructed. The specific steps are as follows: The human CLCA1 cloning vector was purchased from Sino Biological (Cat. No. HG18834-U). The cDNA sequence of CLCA1 was cloned by PCR using the cloning vector as a template. After gel recovery, the cDNA sequence was inserted into the pCMV-C-His (Biyuntian, Cat. No. D2650) vector using homologous recombination technology (Novozymes, Cat. No. C112) for transformation. A single clone was selected for Sanger sequencing to obtain the vector pCMV-CLCA1-C-His with the correct sequence. After obtaining a certain amount of vector by plasmid extraction (Tiangen, catalog number: DP116), the vector was transfected into 293T cells (ATCC, catalog number: CRL-3216) using Lipo2000 transfection reagent (Thermo Fisher, catalog number: 11668027). After 48 hours, the cells were lysed using immunoprecipitation cell lysis buffer (Biyuntian, catalog number: P0013), and then centrifuged at 1000g to obtain the protein containing CLCA1-C-His. The protein solution was then incubated with His-tagged protein agarose high-speed purification resin (Yisheng, catalog number: 20503ES10) and incubated at 4°C for 1 hour to hang the His protein on the column. The agarose resin was then washed 4 times with protein lysis buffer to remove non-specifically adsorbed proteins. The CLCA1-His protein hanging on the column was incubated with the extracted bacterial membrane protein lysate. Then, silver staining was performed using a silver staining reagent. The relevant steps were performed according to the instructions of the silver staining kit (Biyuntian, catalog number: P0017S). Figure 2 As shown in part A, the first lane of the band is CLCA1-C-His without incubation of bacterial membrane protein as input, and the second lane is the group co-incubated with CLCA1-C-His and bacterial membrane protein. By comparing the silver staining results, it was found that there was a significant band at around 35KD, that is, the His-pulldown experiment used CLCA1-His to fish out the pseudo-Bifidobacterium longum cell membrane protein that interacted with CLCA1 at around 35KD; the band was cut off and sent for protein spectrum detection. By analyzing the protein spectrum results, all membrane-associated proteins were selected, and a total of 15 potential target proteins were found.
[0049] (2) In order to further identify the proteins that interact with CLCA1, the fluorescent protein complementation technology was used to further verify the above 15 potential proteins. The relevant steps are as follows: the cDNA sequence of CLCA1 was inserted into the N-terminus of pCMV-nYFP, and the DNA sequences of 15 proteins that could potentially interact with CLCA1 were inserted into the C-terminus of pCMV-cYFP. pCMV-CLCA1-nYFP and 15 pCMV-cYFP were co-transfected into 293T cells. If there is a protein that can interact with CLCA1, then nYFP and cYFP can form a complete YFP molecule, and the fluorescent signal can be observed under a fluorescence microscope. For the protein name obtained by mass spectrometry identification (such as Figure 2 The gene sequence of the corresponding protein was found in the corresponding genome of Bifidobacterium pseudolongum through the NCBI website. According to the sequence information, the corresponding primers were designed, and PCR was performed using the extracted genome of Bifidobacterium pseudolongum as a template. The corresponding PCR product was recovered by gel (as shown in FIG. Figure 2 As shown in Part B of the diagram, the corresponding sequence was inserted into the C-terminus of pCMV-cYFP by homologous recombination. After the construction was successful, 15 corresponding proteins were obtained by plasmid extraction (Tian Gen, Catalog No.: DP105), and then pCMV-CLCA1-nYFP and these 15 protein plasmids were functionally transfected into 293T cells (plasmid transfection was performed using conventional liposome transfection methods, and the transfection reagents used were purchased from Thermo Fisher, Catalog No. 11668027, and the transfection operation was performed according to the instructions). If there is an interaction, a fluorescent signal will be generated. Figure 2 As shown in part C, it was found that only protein No. 1 among the 15 proteins, namely atpH and CLCA1, could produce fluorescent signals after co-transfection.
[0050] (3) Then, the in vitro GST pulldown experiment was performed. The relevant experimental steps were as follows: the atpH gene of Bifidobacterium pseudolongum was inserted into the pGEX-4t-1 (Fenghui Biology, catalog number: YH004) vector by homologous recombination to obtain the pGEX-4t-1-atpH vector, which was transformed into the BL21 competent medium (Weidi Biology, catalog number: EC2200S), and a single clone was picked. Then, when the OD was amplified in LB to 0.3, IPTG (Yisheng, catalog number: 10902ES08) with a final concentration of 0.5mM was added to induce expression. After 8 hours, the bacteria were collected by centrifugation, resuspended in PBS, and the bacteria were broken by ultrasonic disruption to release the induced protein. The broken bacterial solution was centrifuged to obtain a protein solution containing atpH-GST, and then incubated with glutathione (GST) purification resin (Yisheng, catalog number: 20508ES10) for column hanging for use. Then, pCMV-CLCA1-C-His was transfected into 293T cells. After 48 hours, the cells were collected and lysed using Co-IP lysis buffer (Biyuntian, catalog number: P0013). The supernatant was collected after centrifugation. The collected protein supernatant containing CLCA1-C-His and the agarose of the aforementioned atpH-GST column were incubated at 4°C for 4 hours, then centrifuged at low speed to remove the supernatant, and the precipitate was washed 4 times with Co-IP lysis buffer. The agarose resin was finally dissolved with WB loading buffer (Biyuntian, catalog number: P0015G) for subsequent WB identification. The results are as follows: Figure 2 As shown in part C, the Input group was CLCA1-C-His protein as a positive control, the pGEX-4t-1 group was a negative control group, and the pGEX-4t-1-atpH group was a pulldown experimental group. It can be found that a band appeared at the CLCA1-C-His position in the experimental group, but not in the negative control group. The results showed that CLCA1 and atpH can interact directly.
[0051] Example 3- Specificity verification of the interaction between bacterial atpH protein and host CLCA1
[0052] Since atpH protein is an important subunit of the ATP synthesis machine, most living organisms express atpH protein. Therefore, this example further verifies whether the interaction between atpH and host CLCA1 is specific to bifidobacteria or widely present in various microorganisms. The specific method includes:
[0053] Fluorescent protein complementation technology was used to further verify whether atpH on Bifidobacterium (including Bifidobacterium pseudolongum, Bifidobacterium longum), Enterococcus faecalis, Escherichia coli, and Lactobacillus animalis could interact with CLCA1. The experimental results are as follows Figure 3As shown. The results show that Bifidobacterium can basically interact with CLCA1 to produce fluorescent signals, but the common animal Lactobacillus (laboratory self-preserved species), Escherichia coli (Weidi Biological, catalog number: DL1001) and Enterococcus faecalis (laboratory self-preserved species) in the intestine cannot produce fluorescent signals; WB results also show that the above-mentioned related plasmids are expressed, excluding the possibility that the negative fluorescent signal comes from the non-expression of the plasmid. The above results show that the interaction between Bifidobacterium atpH and CLCA1 is species-specific.
[0054] Example 4 - Interaction between Bifidobacterium atpH and CLCA1 can increase Bifidobacterium colonization
[0055] Based on the fact that bifidobacteria can interact with CLCA1 through their own atpH protein, this example further verifies whether the interaction between bacteria and the host will increase the colonization ability of bifidobacteria, and the specific method includes:
[0056] First, the CLCA1 protein was overexpressed in the human intestinal epithelial cell line HIEC6 (ATCC, catalog number: CRL-3266), and then Bifidobacterium pseudolongum and intestinal epithelial cells were co-cultured. The relevant steps are as follows: After the human CLCA1 gene sequence was recovered by PCR gel, the recovered CLCA1 sequence was inserted into the pCDH lentiviral vector using recombinant cloning technology. The constructed lentiviral vector pCDH-CLCA1 and auxiliary plasmids pMD2.G and psPAX2 were co-transfected into 293T cells, and the cell supernatants of 24 and 48 hours of transfection were collected, and the CLCA1 overexpression lentivirus was collected by filtration through a 0.45 micron filter membrane. The obtained CLCA1 lentivirus was added to the HIEC6 culture medium, and Polybrene was added at a final concentration of 10 μg / mL. After 24 hours, the culture medium was discarded and replaced with fresh culture medium. After 48 hours, the HIEC6 cells are CLCA1 overexpressing cells. HICE6 cells overexpressing CLCA1 and Bifidobacterium bacteria were added to the HIEC6 cell culture medium at a ratio of 1:100. The culture plate was placed in an anaerobic incubator, the culture plate was taken out after 4 hours, the cell culture medium was discarded, and the HIEC6 cells were washed 5 times with sterile PBS. The HIEC6 cells were then scraped off with a cell scraper and fixed with electron microscopy fixative (Sevier Bio, G1102-100ML), followed by electron microscopy; alternatively, the cells were treated with 0.1% pre-cooled Triton x-100 solution to rupture the cells, and then the cell lysate was diluted 100 times and applied to Wilkens-Chalgren solid culture medium (Solebo, catalog number: LA4400); the cells were cultured in an anaerobic incubator, and the bifidobacterium single colonies on the solid culture medium were counted after 48 hours. Figure 4As shown in part A of the figure, electron microscopy results show that overexpression of CLCA1 can increase the number of colonization of Bifidobacterium pseudolongum; Figure 4 As shown in parts B and C, the number of colonies on the plate after co-culture of bacteria and intestinal epithelium was also found to be significantly higher in the CLCA1 overexpression group (CLCA1OE group) than in the control group through the determination of the number of colonies on the plate, that is, the overexpression of CLCA1 can increase the colonization of bifidobacteria. The above results show that the interaction between CLCA1 and bifidobacteria can increase the colonization of bifidobacteria. (Statistical analysis was performed using T-test, *p<0.05)
[0057] Example 5- Retinoic acid regulates the expression of host CLCA1 and promotes Bifidobacterium colonization
[0058] Based on the fact that the interaction between host CLCA1 and bifidobacterium atpH can regulate the colonization of bifidobacteria, this example verifies whether the colonization of bifidobacteria can be promoted by regulating the expression of host CLCA1, and the specific method includes:
[0059] (1) First, mouse intestinal organoids were used to evaluate whether retinoic acid could increase the expression of CLCA1 in organoids. The relevant experimental steps were as follows: After the mouse was euthanized, the small intestine segment of the mouse was removed, cut open longitudinally, and the contents inside were removed. The small intestine was cut into small segments of about 2 mm, and the small intestinal tissue was digested at room temperature for 20 minutes using EDTA at a final concentration of 5 mM. After that, the digestion solution was discarded and the small intestine was washed once with PBS. Then 10 mL of PBS solution was taken and the small intestinal segment was repeatedly blown 10 times with a 15 mL pipette. After the intestinal tissue was precipitated, the supernatant was discarded, and the small intestinal segment was blown with 10 mL PBS again for a total of 4 times. The supernatant of the last three times was collected and filtered with a 70 μm filter. The precipitate obtained by centrifugation was the crypt tissue. The crypt tissue was resuspended with a certain amount of intestinal organoid culture medium (Stemcell, catalog number: 06005) and the technique was performed. Then, the crypt tissue and matrix gel were mixed at a ratio of 200 crypt tissues / 20 μL matrix gel (Yisheng, catalog number: 40186ES10), and one drop of matrix gel was added to the culture plate preheated at 37°C, and then placed in the incubator to solidify the matrix gel. Then, a certain amount of intestinal organoid culture medium was added to cover the matrix gel, and a 10 μM final concentration of Y-27632 inhibitor (MCE, catalog number: HY-10071) was added. The culture medium was changed the next day, and fresh culture medium was changed when the culture medium turned yellow in the next few days. Mature small intestinal organoids can be harvested in about 7 days, and then a certain concentration of retinoic acid or 200nM retinoic acid signaling pathway inhibitor BMS493 (MCE, catalog number: HY-108529) can be used to stimulate intestinal organoids, and then the organoids were collected, and TRIzol (Thermo Fish, catalog number: 15596028CN) was used to extract RNA or formaldehyde fixation. The extracted RNA was reverse transcribed using a reverse transcription kit (Yisheng, catalog number: 11141ES10), and then the primers of CLCA1 (F: CTGTCTTCCTCTTGATCCTCCA, R: CGTGGTCTATGGCGATGACG) and mouse Actin (F: GGCTGTATTCCCCTCCATCG, R: CCAGTTGGTAACAATGCCATGT) were used as internal references to quantify the CLCA1 in organoids. The steps of dye-based qPCR (Yisheng, catalog number: 11199ES08) refer to the instruction manual. Fixed mouse organoids were fluorescently stained with CLCA1 antibodies, and the secondary antibody was hybridized with AF488-labeled anti-rabbit secondary antibody (Yisheng, catalog number: 33106ES60). Figure 5 As shown in the immunofluorescence results of part A, staining with the CLCA1 antibody (Abcam, catalog number: ab180851) indicated that 200 nM retinoic acid could significantly increase the expression of CLCA1 in mouse intestinal organoids. Figure 5The quantitative PCR results of part B also showed that retinoic acid RA could significantly increase the transcription of CLCA1, while the stimulation effect was inhibited after adding BMS493, an inhibitor of the retinoic acid signaling pathway, indicating that retinoic acid can indeed promote the expression of CLCA1 through the retinoic acid signaling pathway.
[0060] (2) Afterwards, the promoter region of the CLCA1 protein was analyzed to find the retinoic acid binding site. First, the sequence of 2000 bp upstream and 100 bp downstream of the transcription start site of the human CLCA1 gene (Gene ID: 1179) was found on NCBI, as shown below:
[0061] CTTGTAACCCCTGGCTCCTCACATACCACAAGGCATGGGGGTCTCTCTTTCTAAGCGACTGCCGAAAGGG
[0062] CTGGATGACACAGCCAGGAAGTCTGGGGGGAGATGATCACCTGTAGAAGATGAGAAGGAGCCAAACGCT
[0063] TTTCCTTCCTCTCTCCAAAGGGCTGCTCCAAGGCGTGGTTTCTTTGCACAGCCCCTTAGGAGACAACCCAC
[0064] ACAGGAAGGCAAGGGCGCCTGTGGGCTGGCCTGCTGGGTGTCTCCATTGCAGGGCTTAGTAATGCTCCTC
[0065] CTTTAGTTGCTTCCCAGCCTTCCCTGACTCATTTCCCCATTCCCTCATTCTCACTGCTCTGGGATTAAACTC
[0066] TCAAACTCTTAGCACATATGCCTGCCTTAGGCTCTGTTTTTTAGGGAACCCAGGCAAAGACACATACATTT
[0067] GGGGTCTGAGATATCTTGGAATCTACATTTTTAAATTTTGTATGAATAATAAATGTATATGTATTTTGATA
[0068] TAAAAGCATATTTTGGATCATCTGGACAACCACATTATAATTGAGCATTTCCACTCTATTTCAGTGTTTCC
[0069] CTTTTAACTGCTTAAGATTATGCTAGATATAAAGGGTATTCAATTAGGAAAAGAGGAAGTCAAATTGTCC
[0070] CTGTTTGCAGATGACATGATTGTATATCTAGAAAACCCCATTGTCTCAGGCCCAAAATCTCCTTAAGCTGAT
[0071] AAGCAACTTCAGCAAAGTCTCAGGATACAAAATCAATGTACAAAATCACAAGCATTCTTATACACCAAC
[0072] AACAGACAAACAGAGAGCCAAATCATGAGTGAACTCCCATTCACAATTGCTTCAAAGAGAATAAAATAC
[0073] CTAGGAATCCAACTTACAAGGGACGTGAAGGACCTCTTCAAGGAGAACTACAAACCACTGCTCAAGGAA
[0074] ATAAAAGAGGATACAAACAAATGGAAGAACATTTCATGCTCATGGATAGGAAGAATCAATATCGTGAAA
[0075] ATGGCCATACTGCCCAAGGTAATTTACAGATTCAATGCCATCTCCATCAAGCTACCAATGCCTTTCTTCAC
[0076] AGAATTGGAAAAAACTTACTTTAAAGTTCATATGGACAAGATGAAATTAATGCTTATCACCATCTGAAGAC
[0077] CAAATGAATTTATGAACGAAGAGATATTTCAAGTATTTCAATACAAGAAATGGGGGGGCCAATTTGAGGT
[0078] TCCACCTGAGGTTTGGCAAATTGAAAGAATATACACAGCCACTGACAGCCCATAATTCATGTTCCTAGGG
[0079] ACATTTAGTTTCAGCAAAATAATTTAATGATGTTAATTGGAATTTTATTGACTGGTAGGAGCTATGCAATA
[0080] GAGAAAGCAGAAATCTGATGAGGAACTTGGAGTATGCTTTGCAAAGTAAGATATACATTTTATCTTTACT
[0081] CTCCATTATAAAATAGTCAATAATATCTACATCACTTGCTAATGCTTTTGGTACAAATGGATGTGGAATAT
[0082] AATTGAATATTTTCTTGTTTAAGGGGAGCATGAAGAGGTGTTGAGGTTATGTCAAGGTAAACAAAACCAC
[0083] CATTGTGGTAAAGACCACCATGAGGGATAACTGAATATATGGCTTACAAAATGTTTACTGAATAAGCAGA
[0084] ACAGTCTGGATTTTCCTGGGCAGGAGGGGGTTGGGGGCTTTGGGTGGGTTGGTGTCCATGGCTTGGTAAA
[0085] CATTTCCAAGAAGTAAACAAACCTATCAGCGGCCAAGCTGCTTGTCACCTGTGAGTGCTTCCAAGGAACC
[0086] GGATGTGGGCTCCCCCCACCCCTTACCCCAGCATCTGGCACAGCTGAAGGCAGATGGAAATATTTACAAGTA
[0087] CGCAATTTGAGACTAAGATATTGTTATCATTCTCCTATTGAAGACAAGAGCAATAGTAAAACACATCAGG
[0088] TCAGGGGGTTAAAGACCTGTGATAAACCACTTCCGATAAGTTGGAAACGTGTGTCTATATTTTCATATCTG
[0089] TATATATATAATGGTAAAGAAAGACACCTTCGTAACCCGCATTTTCCAAAGAGAGAAATCACAGGGAGAT
[0090] GTACAGCAATGGGGCCATTTAAGAGTTCTGTGTTCATCTTGATTCTTCACCTTCTAGAAGGGGC
[0091] The JASPER online tool was used to predict the transcription factor binding sites in the promoter region, and the analysis revealed that two potential nuclear factor retinoic acid receptor α (RARα) binding sites were located 509 bp and 849 bp upstream of the start site, respectively. Figure 5 As shown in the schematic diagram of part C. To this end, the Luciferase experiment was used for further verification. The relevant experimental steps are as follows: PCR amplified the promoter sequences 1018bp, 596bp and 317bp upstream of the start site, and inserted the sequences obtained by PCR into the pGL3 basic vector, and then co-transfected with the pRL-TK plasmid into 293T cells. After 24 hours, 0.2μM retinoic acid was used to activate the cells for 24 hours, and then the dual fluorescence reporter gene detection kit (Yishen, catalog number: 11402ES60) was used for detection and analysis. The results are shown in Figure 5 As shown in the D part, at the upstream 596bp position, retinoic acid stimulation has the highest signal, while at the upstream 1018bp position, there is no difference compared with the vector negative control, so it is suggested that the upstream 596bp is most likely the binding site of the RARα nuclear factor in the retinoic acid pathway. In order to further confirm the binding site, the sequence was mutated using point mutation. The relevant process is as follows: Use the single point mutation kit (C214) of Novozymes to design the corresponding mutation primers (F: GAcGTTcTGTCAAGGTAcACAAAACCA CCATTGTGGTAAAGA, R: gTACCTTGACAgAACgTCAACACCTCTTCATGCTCCCC), then construct the mutant plasmid according to the instructions, and then detect it according to the above-mentioned Luciferase experiment method. The results are shown in Figure 5 As shown in part E, the signal is significantly reduced after mutation compared to before mutation, suggesting that this is the binding site of RARα; that is, the retinoic acid binding site is the 509-527bp site upstream of the CLCA1 protein promoter, and the specific sequence is: AGGTTATGTCAAGGTAA.
[0092] (3) Furthermore, the effect of retinoic acid on the expression of ClCA1 in intestinal tissue was also verified in an in vivo mouse experiment. The experimental process is as follows: 8-week-old C57 wild mice were purchased from Shanghai Slake Experimental Animal Co., Ltd., with 6 mice in each group. An Oil control group and a retinoic acid RA treatment group were set up. The mice were gavaged with all-trans retinoic acid (MCE, catalog number: HY-14649) at a dose of 15 mg / kg / day every day, and the control group was fed with the same volume of solvent olive oil. After two weeks, the mice were euthanized, and the intestinal tissues were removed for WB detection. Figure 5 As shown in part F, feeding retinoic acid significantly increased the expression of CLCA1 in the intestinal tissue compared with the vehicle olive oil control group.
[0093] In order to verify that CLCA1 can promote the colonization of bifidobacteria in the mouse intestine and increase the abundance of bifidobacteria in the intestine, the qPCR method was used to determine the abundance of bifidobacteria in mouse feces. The relevant steps are as follows: Two weeks after the mice were gavaged with retinoic acid and olive oil, the feces of each mouse were collected in the sterile operating table of the animal room. About 3 feces were collected from each mouse, and then the fecal genomic DNA extraction kit (Tiangen, catalog number: DP328) was used to extract the fecal genome. Nanodrop was used for DNA quantification, and the concentration of all fecal genomes was adjusted to about 10 ng / μL. The primers of Bifidobacterium (F: TCGCGTCYGGTGTGAAAG, R: CCACATCCAGCRTCCAC) and the 16s primers were used as internal reference primers (F: AAACTCAAAKGAATTGACGG, R: CTCACRRCACGAGCTGAC) for dye method qPCR quantitative analysis. The results are shown in the figure. Figure 5 As shown in the G part, the abundance of Bifidobacterium in the intestinal feces of the group fed with retinoic acid, that is, the RA group, was significantly increased compared with the solvent Oil group. This result shows that retinoic acid can indeed increase the abundance of Bifidobacterium colonization in the intestine. (Statistical analysis was performed using T-test or one-way ANOVA, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001)
[0094] Example 6-Verification of whether vitamin A can increase the expression of CLCA1 in intestinal tissue
[0095] Considering that retinoic acid-like substances can activate the retinoic acid pathway, this example evaluates the effect of vitamin A, the original compound of retinoic acid, to evaluate whether it can also increase the expression of CLCA1 in intestinal tissue like retinoic acid. After constructing mouse organoids in the same manner as in Example 5, the intestinal organoids were stimulated with retinoic acid and vitamin A at the same concentration, and CLCA1 was quantitatively analyzed using qPCR. The results are as follows: Figure 5As shown in the H part, 200nM vitamin A (Merck, catalog number: R1512) can also promote the transcription of CLCA1 in the mouse intestine, but retinoic acid at the same concentration can better induce the transcription of intestinal CLCA1, because retinoic acid is the final executor of the retinoic acid pathway, and vitamin A, as a precursor compound of retinoic acid, needs to be further metabolized into retinoic acid to exert its effect. (Statistical analysis was performed using one-way ANOVA, *p<0.05, ***p<0..001, ****p<0.0001)
[0096] From the experimental results of the above examples, it can be seen that retinoic acid-like substances, such as retinoic acid and vitamin A, can regulate the expression of host CLCA1 through the retinoic acid signaling pathway, thereby promoting the colonization of bifidobacteria. In particular, retinoic acid, as a direct agonist of the retinoic acid signaling pathway, can more effectively increase the expression of CLCA1.
[0097] It can be seen from the above examples that the present invention is the first to use existing drug-like retinoic acid substances to promote the colonization of bifidobacteria by regulating the expression of intestinal CLCA1; the present invention promotes and improves the therapeutic efficacy of bifidobacteria by promoting the colonization of bifidobacteria, and can promote the efficacy of clinical FMT, and shows that CLCA1 can be used as an important evaluation indicator for clinical FMT and bifidobacterium treatment.
[0098] The specific embodiments of the present invention are described in detail above, but they are only examples, and the present invention is not limited to the specific embodiments described above. For those skilled in the art, any equivalent modifications and substitutions made to the present invention are also within the scope of the present invention. Therefore, the equalization changes and modifications made without departing from the spirit and scope of the present invention should be included in the scope of the present invention.
Claims
1. Application of CLCA1 protein expression promoter or inducer in promoting intestinal colonization of Bifidobacterium.
2. The use according to claim 1, characterized in that: The CLCA1 protein expression promoter or inducer increases the expression of CLCA1 protein in intestinal epithelial tissue, and the CLCA1 protein interacts with atpH protein on the surface of bifidobacteria, thereby promoting the colonization of bifidobacteria in the intestine.
3. The use according to claim 1 or 2, characterized in that: The CLCA1 protein expression promoter or inducer includes retinoic acid-like substances, and the retinoic acid-like substances include retinoic acid and vitamin A.
4. The use according to claim 1, characterized in that: The bifidobacterium includes at least one of Bifidobacterium bifidum, Bifidobacterium adolescentis, Bifidobacterium infantis, Bifidobacterium pseudolongum, Bifidobacterium longum, and Bifidobacterium breve.
5. Use of retinoic acid-like substances as promoters or inducers of CLCA1 protein expression.
6. The use according to claim 5, characterized in that: The retinoic acid-like substance includes retinoic acid and vitamin A; a retinoic acid binding site exists in the promoter region of the CLCA1 protein, and the retinoic acid-like substance promotes the expression of the CLCA1 protein in the intestinal epithelial tissue through the retinoic acid signaling pathway.
7. The use according to claim 6, characterized in that: The retinoic acid binding site is the 509-527 bp site upstream of the CLCA1 protein promoter.
8. The use according to any one of claims 5 to 7, characterized in that: The retinoic acid-like substance is used as a CLCA1 protein expression promoter or inducer to promote the colonization of bifidobacteria in the intestine; wherein the retinoic acid-like substance promotes the expression of CLCA1 protein in intestinal epithelial tissue through the retinoic acid signaling pathway, and the CLCA1 protein interacts with the atpH protein on the surface of bifidobacteria, thereby promoting the colonization of bifidobacteria in the intestine.
9. The use according to claim 8, characterized in that: The bifidobacteria include Bifidobacterium bifidum, Bifidobacterium adolescentis, Bifidobacterium infantis, Bifidobacterium pseudolongum, Bifidobacterium longum, and Bifidobacterium breve.
10. The use according to claim 8, characterized in that: The retinoic acid-like substance is used as an adjuvant for intestinal flora transplantation or as an adjuvant for probiotic treatment.
Citation Information
Cited By
Application of bifidobacterium pseudolongum in preparation of leukemia ATO therapy adjuvant drug
CN121513050A
